NCT00003425View on ClinicalTrials.gov

Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 31, 1997

Primary Completion Date

July 31, 2002

Conditions
Breast CancerLeukemiaLymphomaNeuroblastomaOvarian CancerSarcomaUnspecified Adult Solid Tumor, Protocol Specific
Interventions
BIOLOGICAL

filgrastim

DRUG

amifostine trihydrate

DRUG

cyclophosphamide

DRUG

melphalan

PROCEDURE

peripheral blood stem cell transplantation

Trial Locations (4)

21201

Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore

53226

Medical College of Wisconsin, Milwaukee

40536-0084

Albert B. Chandler Medical Center, University of Kentucky, Lexington

19107-5541

Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia

All Listed Sponsors
lead

University of Kentucky

OTHER

NCT00003425 - Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect | Biotech Hunter | Biotech Hunter